Online citations, reference lists, and bibliographies.
← Back to Search

Malignant Mesothelioma: Prognostic Factors In A Prospective Study Of 98 Patients

L. Tammilehto
Published 1992 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
We have prospectively studied 98 patients with histologically confirmed mesothelioma in order to increase our knowledge of the biology of mesothelioma and to assess clinical characteristics, asbestos exposure and S-phase fraction as prognostic factors. Multivariate analysis of the clinical characteristics of the patients (77 men and 21 women) showed that good performance status (WHO ≤ 1), diagnostic delay of more than 6 months, epithelial histology, female gender and clinical stages I or IIA were favourable prognostic factors. Asbestos exposure was estasblished by individual interview (7098 patients) or by lung tissue fibre analysis (2898 patients). Low lung tissue fibre concentration (< 1 × 106 f/g) was a good prognostic factor only in univariate analysis. DNA flow cytometry studies showed diploid predominance in 39 of the 63 tumours analysed; and that a low S-phase fraction was an independent and favourable prognostic factor. In addition to identifying these clinical prognostic factors, our results suggest that the S-phase fraction has independent prognostic significance and that the prognostic importance of asbestos exposure needs to be confirmed.
This paper references
10.1002/IJC.2910410409
Survival patterns for malignant mesothelioma: The seer experience
R. Spirtas (1988)
10.1016/0277-5379(91)90487-X
Diploid predominance and prognostic significance of S-phase cells in malignant mesothelioma.
S. Pyrhönen (1991)
10.1002/AJIM.4700030407
Features of asbestos-exposed and unexposed mesothelioma.
A. Hirsch (1982)
10.1002/1097-0142(19861001)58:7<1540::AID-CNCR2820580727>3.0.CO;2-5
Diffuse malignant mesothelioma of pleura: Diagnosis and survival in 92 cases
V. Adams (1986)
10.1200/JCO.1989.7.8.1157
Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients.
P. Ruffié (1989)
10.1136/thx.38.10.744
Evidence for longer survival of patients with pleural mesothelioma without asbestos exposure.
M. Law (1983)
10.1016/s0147-0272(88)80005-9
Asbestos-related malignancy.
J. Talcott (1988)
10.1136/oem.17.4.260
Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province
J. Wagner (1960)
10.1038/bjc.1989.326
Chromosomal abnormalities and their correlations with asbestos exposure and survival in patients with mesothelioma.
M. Tiainen (1989)
10.1016/0360-3016(92)90709-Q
Multimodality treatment programs for malignant pleural mesothelioma using high-dose hemithorax irradiation.
K. Mattson (1992)
10.1136/oem.48.1.48
Occupational exposure to asbestos as evaluated from work histories and analysis of lung tissues from patients with mesothelioma.
T. Tuomi (1991)
10.1016/0007-0971(83)90068-2
Malignant mesothelioma 1982: review of 4710 published cases.
G. Hillerdal (1983)
10.1177/31.11.6619538
Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry.
D. Hedley (1983)
10.1002/1097-0142(19900415)65:8<1825::AID-CNCR2820650827>3.0.CO;2-H
Diploid predominance in hereditary nonpolyposis colorectal carcinoma evaluated by flow cytometry
M. Kouri (1990)
10.1016/0959-8049(92)90523-5
Malignant mesothelioma: clinical characteristics, asbestos mineralogy and chromosomal abnormalities of 41 patients.
L. Tammilehto (1992)
10.1200/JCO.1988.6.1.147
Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985.
K. Antman (1988)
10.1002/AJIM.4700030305
Occupational exposure to asbestos: population at risk and projected mortality--1980-2030.
W. Nicholson (1982)
10.1136/thx.31.1.15
Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients.
E. Butchart (1976)
10.5271/SJWEH.2559
Inorganic fibers in lung tissue from patients with pleural plaques or malignant mesothelioma.
B. Gylseth (1981)



This paper is referenced by
10.1016/0169-5002(95)00508-0
A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group.
V. Rusch (1996)
10.1016/S0169-5002(99)00044-6
Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma.
H. Schouwink (1999)
Integrin-interacting proteins in human cancer progression
Zhengwen An (2010)
10.1016/j.jtcvs.2008.02.069
The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: implications for revision of the American Joint Committee on Cancer staging system.
R. Flores (2008)
Advances in diagnosis and treatment of malignant mesothelioma
J.P.J.J. Hegmans (2006)
10.1080/10937404.2011.556052
Factors that Impact Susceptibility to Fiber-Induced Health Effects
J. Below (2011)
10.1007/978-0-387-72114-9_12
Neoplasms of the Pleura
S. Hammar (2008)
Prognostic ffactors iin m malignant m mesothelioma: where ddo w we ggo ffrom hhere?
J. Meerbeeck (1994)
10.1378/CHEST.113.3.723
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
10.1016/j.cllc.2012.03.011
Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board.
S. Kao (2013)
10.1016/S1579-2129(06)70085-4
[Pleural mesothelioma: experience with 62 cases in 9 years].
V. Villena Garrido (2004)
10.1200/JCO.1994.12.6.1156
A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma.
V. Rusch (1994)
10.1201/9781420061888_ch34
Toxicological profile for asbestos
G. Hanley (2001)
10.1007/0-387-28274-2_26
Staging of Mesothelioma
R. Flores (2005)
10.1111/j.1699-0463.1998.tb01376.x
Immunoreactivity of pleural malignant mesotheliomas to glutathione S‐transferases
A. Dejmek (1998)
10.1016/S0169-5002(01)00257-4
Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma.
G. Ceresoli (2001)
10.1183/09031936.94.07061029
Prognostic factors in malignant mesothelioma: where do we go from here?
J. Meerbeeck (1994)
10.1378/CHEST.108.4.1122
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)
10.1200/JCO.1998.16.1.145
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
10.1002/1097-0142(20010901)92:5<1224::AID-CNCR1441>3.0.CO;2-U
Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma
A. Thylén (2001)
PROGNOSTICC VALUE OF THE SERUM TUMOUR MARKERSS CYFRA21-1 AND TISSUE POLYPEPTIDE ANTIGENN IN MALIGNANT MESOTHELIOMA
Hugoo Schouwink (2007)
10.1016/S0960-7404(98)00019-X
Malignant pleural mesothelioma: a problematic review.
T. L. Moskal (1998)
Study arm 8435 / Cisplatin + mitomycin 8435 / Cisplatin + doxombicin ( Adriamycin ) 8638 / Carboplatin 8833 / DHAC 8933 / Low-dose trimetrexate 8933 / High-dose trimetrexate 9031 / Cisplatin + DHAC
J. Herndon ()
10.1007/0-387-28274-2_13
Asbestos Mineralogy and Health Effects
M. Doğan (2005)
10.1053/SONC.2002.30299
Prognostic factors in mesothelioma.
J. Steele (2005)
10.1016/S0169-5002(10)80011-X
Clinical features and current treatment of diffuse malignant pleural mesothelioma.
V. Rusch (1995)
10.1016/0169-5002(94)00404-B
Evaluation of the clinical TNM staging system for malignant pleural mesothelioma: an assessment in 88 patients.
L. Tammilehto (1995)
10.2147/CMAR.S95663
Management of malignant pleural effusion: challenges and solutions
E. Penz (2017)
10.1016/J.LUNGCAN.2005.03.009
Prognostic factors in mesothelioma.
J. Steele (2002)
10.1007/3-540-27329-8_7
Prognostische Faktoren und Evaluationskriterien
J. A. Burgers (2005)
Angiogenesis, cyclooxygenase-2 and matrix metalloproteinases in malignant mesothelioma
J. Edwards (2003)
10.2214/AJR.166.2.8553940
The proposed new international TNM staging system for malignant pleural mesothelioma: application to imaging.
E. Patz (1996)
See more
Semantic Scholar Logo Some data provided by SemanticScholar